Renaissance Technologies
ARGS

Renaissance Technologies’s Argos Therapeutics, Inc. ARGS Stock Holding History

Renaissance Technologies’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-11,005
Closed -$99K – 3568
2017
Q1 		$99K Buy
+11,005
New +$696K ﹤0.01% 3084
2016
Q1 		– Sell
-1,780
Closed -$82K – 3737
2015
Q4 		$82K Buy
+1,780
New +$151K ﹤0.01% 3131

Other funds holding ARGS

PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Renaissance Technologies's ARGS Position: Q2 2017 in Review

Renaissance Technologies sold out of Argos Therapeutics, Inc. (ARGS) in Q2 2017, closing a stake of 11,005 shares — an estimated $99K sold.

Renaissance Technologies first reported a position in ARGS in Q4 2015 and held it in 2 quarters. The position peaked at $99K in Q1 2017. 34 funds tracked by Wall St. Rank hold ARGS as of Q2 2017.

  • Renaissance Technologies reported no remaining Argos Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Renaissance Technologies sold 11,005 Argos Therapeutics, Inc. shares in Q2 2017, an estimated $99K.
  • Renaissance Technologies first reported a position in Argos Therapeutics, Inc. in Q4 2015 and held it in 2 quarters.
  • Renaissance Technologies's Argos Therapeutics, Inc. position peaked at $99K in Q1 2017.
  • 34 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q2 2017.

Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.